Selecting the right humanized mouse model is one of the most consequential decisions in immuno-oncology (IO) drug development. As therapeutic targets grow more complex, the predictive value of preclinical data hinges on choosing a model that captures the biology your program depends on. The wrong model can mask safety liabilities, inflate efficacy estimates, and weaken the data supporting regulatory submissions.

Join GemPharmatech for a data-driven webinar on how strategic humanized mouse model selection strengthens preclinical decision-making, sharpens translational relevance, and supports IND-enabling studies. Drawing on real-world case studies, our expert will show how to align model selection with your mechanism of action (MOA), study objectives, timeline, tumor microenvironment of interest, and broader development strategy.

In this webinar, you will learn:

• How model selection shapes preclinical outcomes and IND readiness, illustrated through immuno-oncology case studies

• The key features, strengths, and limitations of five major humanized platforms: PBMC, HSC, HSC-HLA, human cytokine knock-in, and human immune checkpoint knock-in models 

• How these five platforms compare on immune reconstitution, timeline, cost, and translational applicability

Date: Thursday, July 30, 2026

Time: 8:00 AM PDT | 10:00 AM CDT | 11:00 AM EDT | 5:00 PM CEST

Duration: One Hour